MUC16 and breast carcinoma: Additionally, the CDK4/6 inhibitor palbociclib, by downregulating MUC16 expression, exerts an inhibitory effect on the expression of key genes in the breast cancer cell cycle and suppresses ER(-) aggressive breast cancer cells (54).